Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MGMT | P16455 | 1/20 | 0.34 |
| ▸ | FSHR | P23945 | 2/20 | 0.34 |
| ▸ | LHCGR | P22888 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22943217 | 0.90 | MMP2 (0.33) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL26448965 | 0.83 | MMP2 (0.36) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL18761189 | 0.82 | HDAC3 (0.35) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL26448903 | 0.81 | BLM (0.34) | — | |
| SCHEMBL18858993 | 0.81 | MGMT (0.47) | MMP2MMP9MMP8MMP13OPRM1 | |
| SCHEMBL26448986 | 0.80 | LGALS3 (0.35) | MMP2MMP9MMP8MMP13 | |
| SCHEMBL27017059 | 0.80 | MGMT (0.45) | MMP2MMP9MMP8MMP13OPRM1 | |
| SCHEMBL26445761 | 0.74 | CRBN (0.34) | MGMT | |
| SCHEMBL18750481 | 0.74 | CRBN (0.34) | MGMT | |
| SCHEMBL25822100 | 0.73 | LGALS3 (0.40) | MMP2MMP9MMP8MMP13OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | TAP1, TIMCC, CD81 | MMP2 2971/4885MMP9 2522/4885MMP8 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.